Medical/Pharmaceuticals

TREEFROG THERAPEUTICS PICKS-UP BEST POSTER AWARD AT THE INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY (ISCT) ANNUAL MEETING FOR THEIR CELL THERAPY PROGRAM IN PARKINSON'S DISEASE

-  Treefrog will present two posters on their cell therapy program in Parkinson's Disease and their proprietary encapsulation technology, C-Stem™ -   BORDEAUX, France, May 29, 2024 /PRNewswire/ -- TreeFrog Therapeutics  has a busy schedule at the ISCT's 30th annual meeti...

2024-05-29 06:00 2374

GC Cell participates 2024 BIO International Convention, Unveiling its future Blueprint 2.0, as the First Korean Business Forum Sponsor

SAN DIEGO, May 28, 2024 /PRNewswire/ -- GC Cell ,  a leader in the cell and gene therapy (CGT) sector within the biopharmaceutical industry, proudly announces its role as the first Korean Business Forum sponsor at the upcoming 2024 BIO International Convention. Set ...

2024-05-28 23:00 2352

Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD

KYOTO, Japan, May 28, 2024 /PRNewswire/ -- Rege Nephro CO., Ltd. ( https://www.regenephro.co.jp/en ) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a dev...

2024-05-28 23:00 2610

Metabolon Now Includes Spectral Data Files for All Global Discovery Panel Projects

MORRISVILLE, N.C., May 28, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the availability of spectral data fil...

2024-05-28 21:00 1911

AUVON Launches a New Professional TENS Unit "AUVON PT1 Pro", Offering a Drug-free Pain Relief Way at Home

Enjoy Convenient, Professional-grade, and Customizable Pain Relief with AUVON 7000 LEWES, Del., May 28, 2024 /PRNewswire/ -- AUVON, a leading expert in the field of professional pain management, has launched AUVON 7000 TENS Unit Muscle Stimulato...

2024-05-28 20:30 2883

From Research to Practice: Prof. Gang Shen and Smartee's Contributions to the ASO Clinical Day 2024

SYDNEY, May 28, 2024 /PRNewswire/ -- Smartee Denti-Technology, a global leader in clear aligners and digital orthodontic solutions, demonstrated its commitment to transforming research into practical clinical applications at the ASO Clinical Day 2024.5.24. ASO is the largest dental specialist so...

2024-05-28 19:19 2226

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

* Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. * Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innova...

2024-05-28 19:00 2450

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

* Synergistic collaboration to revolutionize age-related therapies worldwide * Deal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an e...

2024-05-28 19:00 2065

Lifespin GmbH and Acıbadem Forge a Groundbreaking Metabolomics Partnership to Advance Personalized Medicine

ISTANBUL and REGENSBURG, Germany, May 28, 2024 /PRNewswire/ -- lifespin GmbH, a pioneer in health status detection software, has teamed up with Acıbadem University (ACU) and Acıbadem Healthcare Group (AHG) to launch a comprehensive precision medicine initiative, a significant stride towards revol...

2024-05-28 14:00 1988

Ovarian tissue transplantation is gaining ground for fertility preservation in young and old, with potential to offset adverse effects of menopause

MANILA, Philippines, May 28, 2024 /PRNewswire/ -- More than 10,000 women and girls around the world facing urgent treatments for cancers and other serious conditions that threatened their fertility have had their motherhood potential preserved by surgical removal and freezing of ovarian tissue. ...

2024-05-28 11:36 2062

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2024-05-28 08:00 3935

Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome

Highlights: * Statistically significant improvement from baseline assessed by both clinicians and caregivers in all four efficacy measures specifically designed for Pitt Hopkins syndrome (Wilcoxon signed rank test p<0.05) * Clinician and caregiver global efficacy measures showed a level of i...

2024-05-27 18:00 2702

Driving a consensus approach to improve the lives and fertility health of women stricken with endometriosis

MANILA, Philippines , May 27, 2024 /PRNewswire/ -- Specialists in reproductive health in theAsia Pacific region are advancing a pathfinding initiative to improve the lives of millions of women around the world who suffer from endometriosis. The debilitating condition affects up to 10 per cent ...

2024-05-27 13:00 2613

Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine "Curcumin" as Effective Treatment for Dyspepsia as Modern Antacids

Chula  Medicine in collaboration with the Department of Thai Traditional and Alternative Medicine and Gastroenterologists from local medical schools proves thatThai curcumin  can help treat dyspepsia as effectively as ant...

2024-05-27 11:00 3952

Telix Submits NDA for New Prostate Cancer Imaging Agent

MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) tothe United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit ("Kit") for th...

2024-05-27 07:21 2712

Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

- Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-powered ICI response prediction models for NSCLC, demonstrating the impact of Lunit SCOPE suite on precision oncology SEOUL, South Korea, May 24, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leadin...

2024-05-24 22:07 6353

Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting

SHANGHAI, May 24, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple advanced solid tumors, which will be reported as an oral pre...

2024-05-24 22:00 6077

Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024

SHANGHAI, May 24, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced latest clinical research results on GC203 (a novel non-viral vector gene-modif...

2024-05-24 20:00 4978

YS Biopharma Announces Name Change to LakeShore Biopharma

GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...

2024-05-24 19:30 2827

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidn...

2024-05-24 19:00 3788
1 ... 224225226227228229230 ... 645

Week's Top Stories